参考文献
Smith, C.C., Beckermann, K.E., Bortone, D.S., De Cubas, A.A., Bixby, L.M.,Lee, S.J., Panda, A., Ganesan, S., Bhanot, G., Wallen, E.M., et al. (2018). Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J. Clin. Invest. 128, 4804–4820.Catherine E Handy & Emmanuel S Antonarakis, Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol. (2018) 14(10), 907–917
Essia Mezni et al,New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices? Cancers 2020, 12, 1573
Goff, S.L., Dudley, M.E., Citrin, D.E., Somerville, R.P., Wunderlich, J.R., Danforth, D.N., Zlott, D.A., Yang, J.C., Sherry, R.M., Kammula, U.S., et al. (2016). Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J. Clin. Oncol. 34, 2389–2397.
Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J.L., Wong, Y.N.S., Rowan, A., Kanu, N., Al Bakir, M., et al. (2017). Insertion-and deletion- derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009–1021.
Lindeboom, R.G.H., Vermeulen, M., Lehner, B., and Supek, F. (2019). The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy. Nat. Genet. 51, 1645–1651.
Wei, Z., Zhou, C., Zhang, Z., Guan, M., Zhang, C., Liu, Z., and Liu, Q. (2019). The landscape of tumor fusion neoantigens: a pan-cancer analysis. iScience 21, 249–260.
Norberg, S.M., Nagarsheth, N., Doran, S., Kanakry, J.A., Adhikary, S., Schweitzer, C., Astrow, S.H., Faquin, W., Gkitsas, N., Highfill, S., and Hinrichs, C.S. (2018). Regression of epithelial cancers following T cell receptor gene therapy targeting human papillomavirus-16 E7. Blood 132, 492.
Kahles, A., Lehmann, K.V., Toussaint, N.C., Huser, M., Stark, S.G., Sachsenberg, T., Stegle, O., Kohlbacher, O., Sander, C., Cancer Genome Atlas Research, N., and Ratsch, G. (2018). Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell 34, 211–224.e6.
Laumont, C.M., Daouda, T., Laverdure, J.P., Bonneil, E., Caron-Lizotte, O., Hardy, M.P., Granados, D.P., Durette, C., Lemieux, S., Thibault, P., and Perreault, C. (2016). Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames. Nat. Commun. 7, 10238.
Faridi, P., Li, C., Ramarathinam, S.H., Vivian, J.P., Illing, P.T., Mifsud, N.A., Ayala, R., Song, J., Gearing, L.J., Hertzog, P.J., et al. (2018). A subset of HLA-I peptides are not genomically templated: evidence for cis- and transspliced peptide ligands. Sci. Immunol. 3, eaar3947.
Zhao, Y.; Baldin, A.V.; Isayev, O.; Werner, J.; Zamyatnin, A.A., Jr.; Bazhin, A.V. Cancer Vaccines: Antigen Selection Strategy. Vaccines 2021, 9, 85.
联系客服